|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-5-24
|
|
pubmed:abstractText |
To study the effectiveness and tolerability of a dose-intensified treatment including rituximab for patients, not older than 65 yr, with high-risk aggressive B-cell lymphoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1357-0560
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
283-93
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16720929-Adult,
pubmed-meshheading:16720929-Aged,
pubmed-meshheading:16720929-Antibodies, Monoclonal,
pubmed-meshheading:16720929-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:16720929-Antimetabolites, Antineoplastic,
pubmed-meshheading:16720929-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16720929-Central Nervous System Neoplasms,
pubmed-meshheading:16720929-Cyclophosphamide,
pubmed-meshheading:16720929-Cytarabine,
pubmed-meshheading:16720929-Disease-Free Survival,
pubmed-meshheading:16720929-Doxorubicin,
pubmed-meshheading:16720929-Etoposide,
pubmed-meshheading:16720929-Female,
pubmed-meshheading:16720929-Follow-Up Studies,
pubmed-meshheading:16720929-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:16720929-Humans,
pubmed-meshheading:16720929-Lymphoma, B-Cell,
pubmed-meshheading:16720929-Male,
pubmed-meshheading:16720929-Middle Aged,
pubmed-meshheading:16720929-Prednisolone,
pubmed-meshheading:16720929-Recombinant Proteins,
pubmed-meshheading:16720929-Recurrence,
pubmed-meshheading:16720929-Retrospective Studies,
pubmed-meshheading:16720929-Vincristine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14).
|
|
pubmed:affiliation |
Department of Oncology, Uppsala University Hospital, 751 85 Uppsala Sweden. Magdalena.Adde@Akademiska.se
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
